论文部分内容阅读
目的探讨抗CD20单克隆抗体(美罗华)在非霍奇金淋巴瘤(NHL)治疗中的疗效。方法应用美罗华联合CHOP方案治疗NHL20例,其中初治18例,难治2例;用于自体造血干细胞移植的体内净化4例;维持治疗5例。结果诱导组20例中初治者18例,15例患者达到了完全缓解(CR),3例达到部分缓解(PR),CR率83%,总有效率100%。难治患者中1例达到PR,1例无疾病进展;未观察到美罗华对采集到的干细胞的质量和数量以及移植后造血恢复有不良影响,4例中2例细胞PCR免疫球蛋白重排(IgH)检测转阴;维持治疗组中5例全部存活(最长随访33个月)。结论美罗华联合化疗方案能够提高CD2+0NHL的疗效,有助于清除微小残留病灶,延长NHL的生存期。
Objective To investigate the efficacy of anti-CD20 monoclonal antibody (rituximab) in the treatment of non-Hodgkin’s lymphoma (NHL). Methods Rituximab combined with CHOP regimen in the treatment of 20 cases of NHL, including initial treatment in 18 cases, refractory in 2 cases; autologous hematopoietic stem cell transplantation in vivo purification in 4 cases; maintenance treatment in 5 cases. Results In the induction group, 18 cases were initially treated in 20 cases, 15 cases achieved complete remission (CR), 3 cases achieved partial remission (PR), the CR rate was 83% and the total effective rate was 100%. One of the refractory patients achieved PR and one had no disease progression. Rituximab was not observed to have adverse effects on the quality and quantity of stem cells collected and the hematopoietic recovery after transplantation. Two of the four patients had PCR immunoglobulin rearrangements IgH) turned negative; all five patients survived in the maintenance treatment group (up to a maximum of 33 months). Conclusion Rituximab combined with chemotherapy can improve the efficacy of CD2 + 0NHL, help to clear the minimal residual lesion and prolong the survival of NHL.